Baseline patient characteristics, univariate analysis and propensity matched groups
| Column | Unmatched groups | Propensity matched groups | ||||
| AC 108 | CDT 18 | P value | AC 17 | CDT 17 | P value | |
| Age | 75.5±7.99 | 73.8±6.19 | 0.329 | 77.6±7.89 | 73.7±6.35 | 0.121 |
| Caucasian | 19 (41.7%) | 5 (27.8%) | 0.464 | 2 (11.7%) | 5 (29.4%) | 0.286 |
| BMI (kg/m2) | 28.8±8.51 | 33.8±7.66 | 0.024 | 30.4±12.2 | 33.9±7.9 | 0.340 |
| Medical History | ||||||
| Hypothyroidism | 12 (11.2%) | 3 (16.7%) | 0.51 | 1 (5.9%) | 3 (17.7) | 0.287 |
| DVT | 15 (14.0%) | 6 (33.3%) | 0.043 | 4 (23.5%) | 6 (35.3%) | 0.452 |
| PE | 10 (9.4%) | 5 (29.4%) | 0.018 | 1 (5.9%) | 5 (29.4%) | 0.072 |
| Malignancy | 33 (30.8%) | 0 | 0.006 | – | – | – |
| Diabetes mellitus | 39 (36.5%) | 3 (16.7) | 0.1 | 7 (41.2%) | 3 (17.6%) | 0.132 |
| COPD | 29 (27.4%) | 2 (11.1%) | 0.141 | 6 (35.3%) | 1 (5.9) | 0.034 |
| Cardiopulmonary | 46 (55.4%) | 8 (53.3%) | 0.881 | 8 (66.7%) | 7 (50.0%) | 0.391 |
| Recent surgery | 23 (21.5%) | 0 | 0.029 | – | – | – |
| AC use | 11 (10.3) | 1 (5.6%) | 0.529 | 2 (11.8%) | 1 (5.9%) | 0.545 |
| IVC filter | 3 (2.8%) | 2 (11.1%) | 0.096 | 1 (5.9%) | 2 (11.8%) | 0.545 |
| CKD | 17 (15.9%) | 2 (11.1%) | 0.601 | 3 (17.7%) | 2 (11.8%) | 0.628 |
| ESRD on RRT | 4 (3.7%) | 0 | 0.404 | 1 (5.9%) | 0 | 0.31 |
| PE severity (ESC) | ||||||
| 1 | 23 (21.5%) | 0 | <0.001 | 0 | 0 | – |
| 2 | 43 (40.2%) | 0 | 0 | 0 | ||
| 3 | 38 (35.5%) | 18 (100%) | 17(100%) | 17(100%) | ||
| 4 | 3 (2.8%) | 0 | 0 | 0 | ||
Bold font indicates statistical significance
AC, anticoagulation; BMI, body mass index; CDT, catheter directed thrombolysis; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DVT, deep vein thrombosis; ESC, European Society of Cardiology; ESRD, end-stage renal disease; IVC, inferior vena cava; PE, Pulmonary embolism; RRT, renal replacement therapy.